Zinc supplementation improves bone density in patients with thalassemia: A double-blind, randomized, placebo-controlled trial

American Journal of Clinical Nutrition

Volumn 98, Issue 4, 2013, Pages 960-971

  Fung, Ellen B ^a   Kwiatkowski, Janet L ^b   Huang, James N ^c   Gildengorin, Ginny ^d   King, Janet C ^e   Vichinsky, Elliott P ^a  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Pediatric Clinical Research Center   (United States)

^e CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; PLACEBO; ZINC SULFATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; BONE DENSITY; BONE MASS; BONE MINERAL; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; MALE; MICROCAPSULE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; THALASSEMIA MAJOR; VITAMIN SUPPLEMENTATION; ZINC BLOOD LEVEL; ZINC DEFICIENCY;

ADOLESCENT; ADULT; BETA-THALASSEMIA; BONE DENSITY; CHILD; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PLACEBOS; YOUNG ADULT; ZINC;

EID: 84884882419     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.112.049221     Document Type: Article

References (51)

1. Cunningham MJ, Macklin E, Neufeld EJ, Cohen AR. Complications of B-thalassemia major in North America. Blood 2004;104:34-9. (Pubitemid 38879833)
2. Yamaguchi M. Role of nutritional zinc in the prevention of osteoporosis. Mol Cell Biochem 2010;338:241-54.
3. Brown KH, Peerson JM, Rivera J, Allen LH. Effect of supplemental zinc on the growth and serum zinc concentrations of pre-pubertal children: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2002;75:1062-71. (Pubitemid 34547537)
4. Prasad AS. Impact of the discovery of human zinc deficiency on health. J Am Coll Nutr 2009;28:257-65.
5. Jansen J, Karges W, Rink L. Zinc and diabetes-clinical links and molecular mechanisms. J Nutr Biochem 2009;20:399-417.
6. Vogiatzi MG, Macklin EA, Fung EB, Cheung A, Lane J, Schneider R, Fleisher R, Vichinsky E, Kirby M, Olivieri N, et al. Bone disease in thalassemia: a frequent and still unresolved problem. J Bone Miner Res 2009;24:543-57.
7. Fung EB, Harmatz PR, MiletM, Coates TD, Thompson AA, Ranalli M, Mignaca R, Scher C, Giardina P, Roberston S, et al. Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia. Bone 2008;43: 162-8.
8. Voskaridou E, Terpos E. New insights into the pathopysiology and management of osteoporosis in patients with beta thalassemia. Br J Haematol 2004;127:127-39. (Pubitemid 39371805)
9. Wonke B, Jensen C, Hanslip JJ, Prescott E, Lalloz M, Layton M, Erten S, Tuck S, Agnew JE, Raja K, et al. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassemia major. J Pediatr Endocrinol Metab 1998;11:795-801.
10. Dundar U, Kupesiz A, Ozdem S, Gilgil E, Tuncer T, Yesilipek A, Gultekin M. Bone metabolism and mineral density in patients with beta-thalassemia major. Saudi Med J 2007;28:1425-9.
11. Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, Hashemi R, Abdollah AH, Aghakhani S, Homayoun H, et al. Metabolic and endocrinologic complications of beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord 2003;3:4-6.
12. Arcasoy A, Cavdar AO. Changes in trace minerals (serum zinc, copper and magnesium) in thalassemia. Acta Haematol 1975;53:341-6.
13. Kajanachumpol S, Tatu T, Sasunakul W, Chaunsumrit A, Hathirat P. Zinc and copper status of thalassemic children. Southeast Asian J Trop Med Public Health 1997;28:877-80. (Pubitemid 127522348)
14. Uysal Z, Akar N, Kemahli S, Dincer N, Arcasoy A. Desferrioxamine and urinary zinc excretion in b-thalassemia major. Pediatr Hematol Oncol 1993;10:257-60. (Pubitemid 23246435)
15. Arcasoy A, Cavdar AO, Cin S, Erten J, Babacan E, Gozdasoglu S, Akar N. Effects of zinc supplementation on linear growth in beta thalassemia (a new approach). Am J Hematol 1987;24:127-36. (Pubitemid 17020779)
16. Golub MS, Keen CL, Gershwin ME, Styne DM, Takeuchi PT, Ontell F, Walter RM, Hendrickx AG. Adolescent growth and maturation in zincdeprived rhesus monkeys. Am J Clin Nutr 1996;64:274-82. (Pubitemid 26287313)
17. Lowe NM, Fraser WB, Jackson MJ. Is there a potential therapeutic value of copper and zinc for osteoporosis? Proc Nutr Soc 2002;61: 181-5. (Pubitemid 34669897)
18. Mutlu M, Argun M, Kilic E, Saraymen R, Yazar S. Magnesium, zinc and copper status in osteoporotic, osteopenic and normal postmenopausal women. J Int Med Res 2007;35:692-5. (Pubitemid 47570490)
19. Herzberg M, Foldes J, Steinberg R, Menczel J. Zinc excretion in osteoporotic women. J Bone Miner Res 1990;5:251-7. (Pubitemid 20140406)
20. Bekheirnia MR, Shahirsaz AA, Kamgar M, Bouzari N, Erfanzadeh G, Pourzahedgilani N, Tabatabaie SM, Abdollah Shamshirsaz A, Kimiagar M, Ezzati F, et al. Serum zinc and its relation to bone mineral density in beta-thalassemia adolescents. Biol Trace Elem Res 2004;97: 215-24. (Pubitemid 38410637)
21. Saltman PD, Strause LG. Role of trace elements in osteoporosis. J Am Coll Nutr 1993;12:384-9.
22. Chung CS, Stookey J, Dare D, Welch R, Nguyen TQ, Roehl R, Peerson JM, King JC, Brown KH. Current dietary zinc intake has a greater effect on fractional zinc absorption than does longer term zinc consumption in healthy adult men. Am J Clin Nutr 2008;87:1224-9. (Pubitemid 351679762)
23. Wessells KR, Jorgensen JM, Hess SY, Woodhouse LR, Peerson JM, Brown KH. Plasma zinc concentration responds rapidly to the initiation and discontinuation of short-term zinc supplementation in healthy men. J Nutr 2010;140:2128-33.
24. Consolini R, Calleri A, Legitimo A, Massei F. Immunological evaluation of patients with beta-thalassemia major. Acta Haematol 2001; 105:7-12. (Pubitemid 32424498)
25. Claster S, Wood JC, Noetzli L, Carson SM, Hofstra TC, Khanna R, Coates TD. Nutritional deficiencies in iron overloaded patients with hemoglobinopathies. Am J Hematol 2009;84:344-8.
26. Morris N, Udry J. Validation of a self-administered instrument to assess stage of adolescent development. J Youth Adolesc 1980; 9:271-80. (Pubitemid 11247388)
27. Killilea AN, Downing KH, Killilea DW. Zinc deficiency reduces paclitaxel efficacy in LNCaP prostate cancer cells. Cancer Lett 2007; 258:70-9. (Pubitemid 47600492)
28. Mares-Perlman JA, Klein BEK, Klein R, Ritter LL, Fisher MR, Freudenheim JL. A diet history questionnaire ranks nutrient intakes in middle-aged and older men and women similarly to multiple food records. J Nutr 1993;123:489-501. (Pubitemid 23084215)
29. Block G, Woods M, Potosky A, Clifford C. Validation of a selfadministered diet history questionnaire using multiple diet records. J Clin Epidemiol 1990;43:1327-35.
30. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for vitamin A, vitamin D, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium and zinc. Washington, DC: National Academy Press, 2001.
31. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy Press, 2011.
32. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. Washington, DC: National Academy Press, 2002.
33. Carter DR, Bouxsein ML, Marcus R. in: New Approaches for Interpreting Projected Bone Densitometry Data. J Bone Miner Res 1992;7: 137-45.
34. Fung EB, Kawchak DA, Zemel BS, Rovner AJ, Ohene-Frempong K, Stallings VA. Markers of bone turnover are associated with growth and development in young subjects with sickle cell anemia. Pediatr Blood Cancer 2008;50:620-3. (Pubitemid 351155836)
35. Fung EB, Kawchak DA, Zemel BS, Ohene-Frempong K, Stallings VA. Plasma zinc is an insensitive predictor of zinc status: use of plasma zinc in children with sickle cell disease. Nutr Clin Pract 2002;17: 365-72.
36. Suzuki H, Asakawa A, Li JB, Tsai M, Amitani H, Ohinata K, Komai M, Inui A. Zinc as an appetite stimulator-the possible role of zinc in the progression of diseases such as cachexia and sarcopenia. Recent Pat Food Nutr Agric. 2011;3:226-31.
37. al-Refaie FN, Wonke B, Wickens DC, Aydinok Y, Fielding A, Hoffbrand AV. Zinc concentration in patients with iron-overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine. J Clin Pathol 1994;47:657-60.
38. Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol 2009;122:155-64.
39. Fung EB, Vichinsky EP, Kwiatkowski JK, Huang J, Bachrach LK, Sawyer AJ, Zemel BS. Characterization of low bone mass in young patients with thalassemia by DXA, pQCT and markers of bone turnover. Bone 2011;48:1305-12.
40. Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, Kastritis E, Papatheodorou A, Terpos E. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. Haematologica 2009;94:725-8.
41. Mahachoklertwattana P, Srikulchayanonta V, Chuansumrit A, Karnsombat P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R. Bone hisomorphometry in children and adolscents with beta-thalasemia disease: iron associated focal osteomalacia. J Clin Endocrinol Metab 2003;88:3966-72.
42. Gaudio A, Morabito N, Xourafa A, Macri I, Meo A, Morgante S, Trifiletti A, Lasco A, Frisina N. Bisphosphonates in the treatment of thalassemia associated osteoporosis. J Endocrinol Invest 2008;31: 181-4. (Pubitemid 351596981)
43. Voskaridou E, Terpos E. Pathogenesis and management of osteoporosis in thalassemia. Pediatr Endocrinol Rev 2008;6(suppl 1):86-93.
44. Chatterjee R, Bajoria R. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin 2009;33(Suppl 1):S136-8.
45. Zhang J, Saag KG, Curtis JR. Long-term safety concerns of antiresorptive therapy. Rheum Dis Clin North Am 2011;37:387-400 (vi.).
46. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, Recker RR, Shane E, Shoback D, Potts JT. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab 2012;97:2272-82.
47. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with B-thalassemia. Br J Haematol 2003;123:730-7. (Pubitemid 37468072)
48. Mamtani M, Kulkarni H. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. Osteoporos Int 2010;21:183-7.
49. Vogiatzi MG, Macklin EA, Trachtenberg FL, Fung EB, Cheung AM, Vichinski E, Olivieri N, Kirby M, Kwiatkowski JL, Cunningham M, et al. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassemia syndromes in North America. Br J Haematol 2009;146:546-56.
50. Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, Stitchantrakul W, Kanokkantapong C, Rajatanavin R. Abnormalities in bone mineral density and bone histology in thalassemia. J Bone Miner Res 2003;18:1682-8. (Pubitemid 37022927)
51. Sun JY, Wang JF, Zi NT, Jing MY, Weng XY. Effects of zinc supplementation and deficiency on bone metabolism and related gene expression in rat. Biol Trace Elem Res 2011;143:394-402.